Triglav Skladi D.O.O. Acquires New Position in Edwards Lifesciences Co. (NYSE:EW)

Triglav Skladi D.O.O. bought a new stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 20,060 shares of the medical research company's stock, valued at approximately $1,485,000.

Other large investors have also recently bought and sold shares of the company. Sivik Global Healthcare LLC acquired a new stake in Edwards Lifesciences during the 4th quarter valued at $3,702,000. Farmers & Merchants Investments Inc. grew its holdings in Edwards Lifesciences by 21.1% during the 4th quarter. Farmers & Merchants Investments Inc. now owns 134,341 shares of the medical research company's stock valued at $9,945,000 after buying an additional 23,409 shares during the last quarter. Lockheed Martin Investment Management Co. acquired a new stake in Edwards Lifesciences during the 4th quarter valued at $4,499,000. Union Bancaire Privee UBP SA acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth $1,120,000. Finally, Diversify Wealth Management LLC boosted its holdings in shares of Edwards Lifesciences by 99.9% during the fourth quarter. Diversify Wealth Management LLC now owns 37,441 shares of the medical research company's stock worth $2,749,000 after purchasing an additional 18,715 shares during the last quarter. Institutional investors and hedge funds own 79.46% of the company's stock.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Donald E. Bobo, Jr. sold 9,500 shares of Edwards Lifesciences stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $67.96, for a total transaction of $645,620.00. Following the sale, the vice president now directly owns 46,936 shares of the company's stock, valued at approximately $3,189,770.56. The trade was a 16.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 400 shares of Edwards Lifesciences stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.48, for a total value of $27,792.00. Following the sale, the vice president now directly owns 22,588 shares in the company, valued at approximately $1,569,414.24. The trade was a 1.74% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 67,692 shares of company stock valued at $4,822,074 over the last three months. 1.29% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

EW has been the topic of several analyst reports. Citigroup restated a "buy" rating and set a $95.00 price objective (up previously from $84.00) on shares of Edwards Lifesciences in a report on Thursday. Royal Bank of Canada restated an "outperform" rating and set a $85.00 price objective on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Piper Sandler raised their price objective on Edwards Lifesciences from $80.00 to $83.00 and gave the stock an "overweight" rating in a report on Tuesday, May 13th. Stifel Nicolaus upgraded Edwards Lifesciences from a "hold" rating to a "buy" rating and raised their price objective for the stock from $75.00 to $90.00 in a report on Thursday, January 30th. Finally, Evercore ISI decreased their price objective on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $80.20.

Edwards Lifesciences Stock Up 0.3%

NYSE:EW traded up $0.19 during mid-day trading on Friday, hitting $74.98. The company had a trading volume of 3,738,140 shares, compared to its average volume of 5,138,901. The business has a fifty day simple moving average of $72.78 and a 200-day simple moving average of $72.04. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $95.25. The firm has a market capitalization of $43.98 billion, a price-to-earnings ratio of 10.76, a PEG ratio of 4.82 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The company had revenue of $1.41 billion for the quarter, compared to analyst estimates of $1.40 billion. During the same period last year, the company posted $0.66 earnings per share. The firm's revenue was up 6.2% compared to the same quarter last year. Equities analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.